Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series
Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown efficacy in treating cancers with homologous recombination deficiency (HRD), including subsets of melanoma. However, the potential synergy between PARPi and standard melanoma therapies remains understudied. Here, we report two cases of advan...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2025-12-01
|
| シリーズ: | Melanoma Management |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/20450885.2025.2598476 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|